Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR8 | P51685 | 3/20 | 0.60 |
| ▸ | FAAH | O00519 | 3/20 | 0.60 |
| ▸ | MGLL | Q99685 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | TRPV6 | Q9H1D0 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14456739 | 1.00 | CCR8 (0.60) | CCR8FAAHMGLLCYP3A4CYP2D6 | |
| SCHEMBL14456817 | 0.93 | FAAH (0.69) | FAAH | |
| SCHEMBL14456824 | 0.92 | FAAH (0.58) | CCR8FAAHCYP3A4CYP2D6KDM4E | |
| SCHEMBL14456815 | 0.92 | TP53 (0.60) | FAAHMGLLCYP3A4CYP2D6SMN1; SMN2 | |
| SCHEMBL14456776 | 0.90 | KDM4E (0.70) | FAAHCYP3A4CYP2D6KDM4EALDH1A1 | |
| SCHEMBL14456818 | 0.90 | FAAH (0.60) | CCR8FAAHCYP3A4CYP2D6KDM4E | |
| SCHEMBL14456811 | 0.89 | CYP3A4 (0.71) | CYP3A4CYP2D6KDM4EALDH1A1MEN1 | |
| SCHEMBL14456822 | 0.89 | FAAH (0.59) | FAAHCYP3A4CYP2D6KDM4EALDH1A1 | |
| SCHEMBL14456748 | 0.88 | KMT2A (0.73) | CYP3A4CYP2D6KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL14456812 | 0.86 | CYP3A4 (0.56) | CYP3A4CYP2D6KDM4EALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | CCR8 2718/4885FAAH 15/4885MGLL 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.